Clinical Trials Browser

Phase 2 × aldesleukin × Dermatologic × Clear all

NCT05155033 2026-05-29

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Phase 2 Recruiting

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT02621021 2026-05-08

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

Phase 2 Recruiting

Melanoma, Skin Neoplasms

NCT04562129 2026-04-01

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Phase 2 Recruiting

Melanoma, Skin Neoplasms

NCT00338377 2026-03-20

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Phase 2 Active not recruiting

Melanoma, Meningeal Neoplasms

NCT01659151 2026-02-20

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

Phase 2 Completed

17 enrolled 11 charts

Melanoma, Neoplasm Metastasis

NCT07288073 2026-02-13

TIL Therapy in cSCC and MCC

Phase 2 Recruiting

Skin Neoplasms, Carcinoma, Merkel Cell

NCT01319565 2025-12-19

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

Phase 2 Completed

102 enrolled 12 charts

Melanoma, Skin Neoplasms

NCT02500576 2025-01-15

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

Phase 2 Completed

18 enrolled 13 charts

Melanoma

NCT02027935 2024-10-08

CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma

Phase 2 Completed

16 enrolled 8 charts

Melanoma

NCT02748564 2023-08-03

Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Phase 2 Terminated

10 enrolled 13 charts

Melanoma

NCT02203604 2023-07-18

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Phase 2 Terminated

9 enrolled 13 charts

Melanoma

NCT01993719 2023-01-18

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Phase 2 Completed

33 enrolled 21 charts

Melanoma

NCT01807182 2022-11-10

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

Phase 2 Completed

11 enrolled 12 charts

Melanoma

NCT00910650 2021-12-06

F5

Phase 2 Completed

14 enrolled 8 charts

Melanoma

NCT00553618 2021-10-29

DTIC

Phase 2 Active not recruiting

Melanoma

NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

Phase 2 Completed

11 enrolled 12 charts

BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

NCT00505635 2020-09-24

Biochemotherapy With Temozolomide for Metastatic Melanoma

Phase 2 Terminated

5 enrolled 5 charts

Melanoma

NCT01266603 2020-02-19

High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI

Phase 2 Completed

44 enrolled 11 charts

Melanoma

NCT01369875 2019-12-10

Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

Phase 2 Terminated

2 enrolled 8 charts

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT00670748 2019-11-19

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

Phase 2 Terminated

45 enrolled 15 charts

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis

NCT01883323 2019-11-08

Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma

Phase 2 Completed

Melanoma, Neoplasm Metastasis

NCT01258855 2019-05-10

Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Phase 2 Completed

84 enrolled 13 charts

Melanoma

NCT01814046 2018-10-11

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

Phase 2 Terminated

24 enrolled 13 charts

Uveal Melanoma, Neoplasm Metastasis

NCT00726739 2017-12-28

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

Phase 2 Completed

21 enrolled 12 charts

Melanoma

NCT02111863 2017-09-19

Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Phase 2 Terminated

6 enrolled 9 charts

Melanoma, Skin Neoplasms

NCT01271907 2017-08-01

Drosophila-generated CTL

Phase 2 Terminated

3 enrolled 8 charts

Melanoma, Neoplasms, Skin Neoplasms

NCT01754376 2017-04-12

Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

Phase 2 Terminated

6 enrolled 12 charts

Melanoma, Neoplasm Metastasis

NCT02062359 2016-06-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma

Phase 2 Terminated

2 enrolled 7 charts

Melanoma, Neoplasm Metastasis

NCT00096382 2015-10-28

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

34 enrolled 11 charts

Melanoma

NCT00610311 2015-10-28

Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma

Phase 2 Terminated

3 enrolled 10 charts

Melanoma, Skin Neoplasms

NCT00612222 2015-10-28

Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma

Phase 2 Terminated

4 enrolled 9 charts

Melanoma, Skin Neoplasms

NCT00704938 2015-10-28

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

Phase 2 Terminated

3 enrolled 8 charts

DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

NCT00706992 2015-10-28

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

Phase 2 Terminated

50 enrolled 13 charts

Melanoma

NCT00923195 2015-10-28

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Phase 2 Completed

4 enrolled 11 charts

Melanoma, Skin Neoplasms

NCT01160445 2015-10-28

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

Phase 2 Terminated

9 enrolled 9 charts

DermatologicGenitourinary

Kidney Neoplasms, Melanoma

NCT00665470 2015-10-19

Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma

Phase 2 Completed

10 enrolled 9 charts

Melanoma, Skin Neoplasms

NCT01495572 2015-10-15

Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells

Phase 2 Terminated

5 enrolled 9 charts

Melanoma, Skin Neoplasms

NCT01118091 2015-10-08

Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...

Phase 2 Completed

12 enrolled 10 charts

Melanoma, Skin Neoplasms

NCT01480323 2015-07-21

A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2

Phase 2 Completed

Melanoma

NCT00003222 2014-12-19

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Phase 2 Completed

40 enrolled 10 charts

Melanoma

NCT00006113 2014-05-22

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Phase 2 Terminated

Melanoma

NCT00002845 2013-12-19

Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Unknown

Melanoma

NCT00002535 2013-06-26

Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma

Phase 2 Completed

Melanoma

NCT00003568 2013-06-26

Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00019331 2013-06-20

Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

Phase 2 Completed

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Testicular Germ Cell Tumor, Squamous Cell Carcinoma of Head and Neck, Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Salivary Gland Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT00019383 2013-06-20

Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00019487 2013-06-20

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00019669 2013-06-20

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00019721 2013-06-20

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00019734 2013-06-20

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma